Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $1.8 million.

  • Prime Medicine's Change in Accured Expenses fell 118.06% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 164.53%. This contributed to the annual value of $1.8 million for FY2024, which is 4.84% up from last year.
  • As of FY2024, Prime Medicine's Change in Accured Expenses stood at $1.8 million, which was up 4.84% from $1.8 million recorded in FY2023.
  • Over the past 5 years, Prime Medicine's Change in Accured Expenses peaked at $35.2 million during FY2021, and registered a low of -$25.9 million during FY2022.
  • For the 3-year period, Prime Medicine's Change in Accured Expenses averaged around -$7.4 million, with its median value being $1.8 million (2023).
  • As far as peak fluctuations go, Prime Medicine's Change in Accured Expenses soared by 11,557.62% in 2021, and later slumped by 173.49% in 2022.
  • Over the past 5 years, Prime Medicine's Change in Accured Expenses (Yearly) stood at $302,000 in 2020, then skyrocketed by 11,557.62% to $35.2 million in 2021, then plummeted by 173.49% to -$25.9 million in 2022, then surged by 106.79% to $1.8 million in 2023, then climbed by 4.84% to $1.8 million in 2024.